PUBLIC COMPANY
save$ELVNEnliven Therapeutics, Inc.
$ELVN46.51+1.09%Boulder, CO, USupdated 1d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- phase1ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- phase1ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- phase1ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (2)
- Apr 17, 26option exerciseCollins Helen Louise · CHIEF MEDICAL OFFICER5,000 sh
- Apr 17, 26option exerciseCollins Helen Louise · CHIEF MEDICAL OFFICER5,000 sh
🐶 Hiring Signal
News
- Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory studyPlus news about Caribou, Adial, and the Beneluxa Initiative. 💵 Enliven Therapeutics’ data and raise: The Burlingame, CA-based biotech priced a $400 million offering {$ELVN} Thursday night after sa…endpoints · 3mo ago
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.biopharma_dive · 3mo ago
- STAT+: Enliven Therapeutics’ leukemia drug shows promise in new studyA targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, new data show.stat · 3mo ago
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that